NDA 022283 · Riley Consumer
Zegerid Otc
Omeprazole, Sodium Bicarbonate · Oral
Last checked: Nov 20, 2026Latest source record: Nov 23, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Jun 17, 2013
Approved uses
1
Original approval plus efficacy supplements
Registered trials
988
158 Phase 3, 48 recruiting
FAERS reports
339
294 serious, 29 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ZEGERID OTC · OMEPRAZOLE 20MG/PACKET; SODIUM BICARBONATE 1.68GM/PACKET · FOR SUSPENSION, ORAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Omeprazole" as an intervention, any sponsor and status, largest first.
- Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)Pivotal-lookingTerminated
Cogentus PharmaceuticalsIndustry
NCT00557921 · 5,000 participants (planned) · Start Dec 2007 · Primary completion Nov 2009
Drug: CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin; Plavix (clopidogrel 75 mg) and aspirin · For: Acute Coronary Syndrome; Myocardial Infarction; Coronary Artery Disease and 1 more
Sites: Alexander City, Alabama; Birmingham, Alabama; Geneva, Alabama · 491 sites in all
- Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled TrialPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT06943794 · 4,824 participants (planned) · Start Mar 30, 2026 · Primary completion May 1, 2030
Drug: recommendations for Hp eradication treatment · For: Gastric (Stomach) Cancer
Sites: Tongling, China
- Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With ArthritisPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00141102 · 4,484 participants · Start Oct 2005 · Primary completion May 2009
Drug: Celecoxib; Diclofenac + Omeprazole · For: Osteoarthritis; Arthritis, Rheumatoid
Sites: Genk, Belgium; Ghent, Belgium; Hasselt, Belgium · 194 sites in all
- A Randomized Multi-Intervention Trial to Inhibit Precancerous Gastric Lesions in Lingu, Shandong ProvincePivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00339768 · 3,411 participants · Start Jul 1, 1995 · Primary completion Jun 10, 1996
Drug: Amoxicillin/omeprazole · For: Precancerous Gastric Lesions
Sites: Beijing, China
- Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD PatientsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00444275 · 3,029 participants · Start Mar 2007 · Primary completion Oct 2008
Drug: esomeprazole (Nexium®); Xolaam® · For: GERD
Sites: Rouen, France
- A Multi-center Study for Individual Treatment of Helicobacter Pylori InfectionPivotal-lookingStatus unknown
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
NCT02689583 · 3,000 participants (planned) · Start Mar 2016 · Primary completion Mar 2017
Drug: Antibiotic selection based on the antibiotic susceptibility testing · For: Gastritis; Gastric Ulcer
- Helicobacter Pylori Eradication to Prevent Gastric CancerPivotal-lookingActive, not recruiting
Jie-Jun WangAcademic, hospital or other
NCT01133951 · 3,000 participants · Start Jun 2010 · Primary completion Jan 2012
Drug: OAC triple therapy; Placebo · For: Helicobacter Infections; Stomach Neoplasms
Sites: Yangzhong, China
- A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's MetaplasiaPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00357682 · 2,557 participants · Start Mar 10, 2005 · Primary completion May 31, 2017
Drug: Esomeprazole; Esomeprazole and 1 more · For: Esophageal Cancer; Precancerous Condition
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- chronic kidney disease224
- acute kidney injury120
- renal failure112
- renal injury82
- end stage renal disease65
- tubulointerstitial nephritis38
- gastrooesophageal reflux disease28
- nephrogenic anaemia25
- rebound acid hypersecretion25
- nephropathy15
- death13
- renal impairment12
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 2 |
| 2011 | 11 |
| 2012 | 6 |
| 2013 | 5 |
| 2014 | 6 |
| 2015 | 2 |
| 2016 | 9 |
| 2017 | 14 |
| 2018 | 46 |
| 2019 | 153 |
| 2020 | 28 |
| 2021 | 23 |
| 2022 | 9 |
| 2023 | 9 |
| 2024 | 7 |
| 2025 | 3 |
| 2026 | 6 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Clopidogrel with or without omeprazole in coronary artery disease.
Bhatt DL, Cryer BL, Contant CF, et al. · N Engl J Med 2010 · Clinical Trial, Phase III, Multicenter Study
- Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis.
Qi Q, Wang R, Liu L, et al. · Int J Clin Pharmacol Ther 2015 · Comparative Study, Meta-Analysis
- Curcuma longa Linn versus omeprazole in treatment of functional dyspepsia: A randomized, double-blind, placebo-controlled trial.
Yongwatana K, Harinwan K, Chirapongsathorn S, et al. · J Gastroenterol Hepatol 2022 · Randomized Controlled Trial
- Omeprazole promotes proximal duodenal mucosal bicarbonate secretion in humans.
Mertz-Nielsen A, Hillingsø J, Bukhave K, et al. · Gut 1996 · Clinical Trial, Comparative Study
- Efficacy and Safety of Clopidogrel With and Without a Proton Pump Inhibitor: A Systematic Review and Meta-Analysis.
Axelsson MAB, Parodi López N, Wikström Jonsson E, et al. · Basic Clin Pharmacol Toxicol 2025 · Systematic Review, Meta-Analysis
- The clinical efficacy and safety of atropine combined with omeprazole in the treatment of patients with acute gastritis: a systematic review and meta-analysis.
Lin X, Chen H, Lin YN · Ann Palliat Med 2021 · Meta-Analysis, Systematic Review
Sponsor: Riley Consumer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.